#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "Molecular mechanism of oxidation-induced TDP-43 RRM1 aggregation and loss of function."
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Yojana Gadiya"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/conso
# --------------------------------------------------------
 DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns"
 DEFINE NAMESPACE CONSO          AS URL "https://raw.githubusercontent.com/pharmacome/conso/4aa36980578c7d2cff07371abf768f15db89cd11/export/conso-names.belns"
# DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns"
 DEFINE NAMESPACE DOID           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns"
# DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
# DEFINE NAMESPACE EFO            AS URL "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns"
# DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns"
# DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns"
# DEFINE NAMESPACE HP             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/hp-names.belns"
 DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns"
# DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns"
 DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/conso/f02c6ad4a4791a8ed45448513b9de8c8f1b00c87/external/mesh-names.belns"
# DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mgi-names.belns"
# DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"
# DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ncbigene.belns"
# DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/pfam-names.belns"
# DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
# DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
# DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
# DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
# DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
# DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"
 DEFINE NAMESPACE NCIT           AS PATTERN "^C\d+$"
 DEFINE NAMESPACE OMIT           AS PATTERN "^\d{7}$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"
DEFINE ANNOTATION Interaction AS PATTERN "^VariO:\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
# DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
# DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
# DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
# DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
# DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
 DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
# DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
# DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
# DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
# DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
# DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############
SET Citation = {"PubMed", "23384725"}

SET Evidence = "Although originally identified as a transcriptional repressor of type 1 human immunodeficiency virus (HIV-1) DNA [2], it was later shown to play a role in RNA processing and transcriptional regulation [3–5]."
#it - TDP-43
SET Disease = "human immunodeficiency virus infectious disease"
act(p(HGNC:TARDBP), ma(MESH:"Repressor Proteins")) -| a(MESH:"DNA, Viral")
UNSET Disease

SET Evidence = "Large-scale RNA-sequencing studies revealed TDP-43-binding sites on a large number of mRNAs, with many of them involved in synaptic function and neuronal development [6,7]."
p(HGNC:TARDBP) -- bp(GO:"synaptic signaling")
p(HGNC:TARDBP) -- bp(NCIT:C19375)

SET Evidence = "TDP-43 has been found to be a major component of pathological inclusions obtained from patients afflicted with amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) [8]."
p(HGNC:TARDBP) -- path(DOID:"amyotrophic lateral sclerosis")
p(HGNC:TARDBP) -- path(OMIT:0026893)

SET Evidence = "TDP-43 inclusions have also been identified as secondary pathological features in a wide spectrum of neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD) [9]."
composite(p(HGNC:TARDBP), a(MESH:"Inclusion Bodies")) -- path(DOID:"Alzheimer's disease")
composite(p(HGNC:TARDBP), a(MESH:"Inclusion Bodies")) -- path(DOID:"Parkinson's disease")
composite(p(HGNC:TARDBP), a(MESH:"Inclusion Bodies")) -- path(DOID:"Huntington's disease")

SET Evidence = "Structural studies revealed that TDP-43 is arranged into four domains (Fig. 1A): an N-terminal domain (NTD) that is partially structured and is probably involved in protein oligomerization [10], followed by two RNA-recognition motifs (RRM1 and RRM2) capable of binding nucleic acids [11,12], and ending in an intrinsically
disordered C-terminal domain (CTD) implicated in protein interactions [13–15]"
#N-terminal - 1 - 105
#RRM1 - 101 - 191
#RRM2 - 192 - 265
#CTD - 266 - 414
 p(HGNC:TARDBP, frag("1_105")) -- p(CONSO:"TDP-43 oligomers")
 p(HGNC:TARDBP, frag("101_191")) -- act(p(HGNC:TARDBP, frag("101_191")), ma(GO:"nucleic acid binding"))
 p(HGNC:TARDBP, frag("192_265")) -- act(p(HGNC:TARDBP, frag("192_265")), ma(GO:"nucleic acid binding"))
 p(HGNC:TARDBP, frag("266_414")) -- bp(NCIT:C18469)

SET Evidence = "Oxidized TDP-43 also lost the ability to inhibit splicing, suggesting that oxidation of TDP-43 is a loss-of-function event."
 p(HGNC:TARDBP, pmod(GO:"protein oxidation")) -| bp(GO:"RNA splicing")
SET Evidence = "Addition of a reducing agent such as DTT to RRM1 10 min after the start of oxidation treatment prevented protein aggregation."
composite(p(HGNC:TARDBP, frag("101_191")), a(CHEBI:"1,4-dithiothreitol")) =| p(CONSO:"TDP-43 aggregates")

SET Evidence = "Lower amount (1 mM) of H2O2 also induced RRM1 aggregation at a slower rate (Supplemental Figure S1), indicating that the aggregation process is not due to an extraneous amount of oxidant"
composite(p(HGNC:TARDBP, frag("101_191")), a(CHEBI:"hydrogen peroxide")) -| p(CONSO:"TDP-43 aggregates")
a(MESH:Oxidants) cnc p(CONSO:"TDP-43 aggregates")

SET Evidence = "This suggested that inclusion of RRM2 enhanced the aggregation of RRM1 under oxidizing conditions"
#oxidizing conditions
composite(p(HGNC:TARDBP, frag("101_191")), p(HGNC:TARDBP, frag("192_265"))) => p(CONSO:"TDP-43 aggregates")

SET Evidence = "Thus, oxidation of both cysteines in RRM1 is necessary, but not sufficient, to produce insoluble
aggregates."
#RRM1 - C173, C175
p(HGNC:TARDBP, frag("101_191"), pmod(GO:"protein oxidation", Cys,173)) -- p(CONSO:"TDP-43 aggregates")
p(HGNC:TARDBP, frag("101_191"), pmod(GO:"protein oxidation", Cys,175)) -- p(CONSO:"TDP-43 aggregates")

SET Evidence = "On the other hand, the insoluble fraction was almost exclusively composed of disulfide-linked oligomers, with dimer being the predominant species, suggesting that inter-molecular disulfide bridge formation of RRM1 is necessary for aggregate formation."
SET Interaction = "VariO:0281"
composite(p(HGNC:TARDBP, frag("101_191")), p(HGNC:TARDBP, frag("101_191"))) -> p(CONSO:"TDP-43 aggregates")
UNSET Interaction

SET Evidence = "These results indicate that oxidation of RRM1 cysteines impaired its nucleic acid-binding activity."
p(HGNC:TARDBP, frag("101_191"), pmod(GO:"protein oxidation", Cys,173)) neg act(p(HGNC:TARDBP, frag("101_191")), ma(GO:"nucleic acid binding"))
p(HGNC:TARDBP, frag("101_191"), pmod(GO:"protein oxidation", Cys,175)) neg act(p(HGNC:TARDBP, frag("101_191")), ma(GO:"nucleic acid binding"))

SET Evidence = "Between the two cysteines, Cys173 showed much stronger perturbation than Cys175, and since the soluble protein was primarily oxidized at a single cysteine (Fig. 2C), these results strongly suggested that Cys173 is preferentially oxidized over Cys175."
#results in conformational change
p(HGNC:TARDBP, frag("101_191"), pmod(GO:"protein oxidation", Cys,173)) neg path(MESH:"Protein Conformation")
p(HGNC:TARDBP, frag("101_191"), pmod(GO:"protein oxidation", Cys,175)) -- path(MESH:"Protein Conformation")
